Trevi Therapeutics (NASDAQ:TRVI) Raised to Strong-Buy at BMO Capital Markets

by · The Cerbat Gem

Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) was upgraded by research analysts at BMO Capital Markets to a “strong-buy” rating in a research note issued on Monday,Zacks.com reports.

Several other equities research analysts also recently weighed in on TRVI. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Trevi Therapeutics in a report on Friday. Wall Street Zen raised shares of Trevi Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 20th. Morgan Stanley restated an “overweight” rating and set a $20.00 price target on shares of Trevi Therapeutics in a research report on Wednesday, May 6th. Stifel Nicolaus set a $30.00 price target on shares of Trevi Therapeutics in a research note on Friday, May 8th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $19.00 price objective on shares of Trevi Therapeutics in a report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $24.91.

Read Our Latest Research Report on TRVI

Trevi Therapeutics Price Performance

Shares of Trevi Therapeutics stock opened at $18.18 on Monday. Trevi Therapeutics has a 1-year low of $6.55 and a 1-year high of $20.22. The business’s fifty day moving average price is $15.96 and its two-hundred day moving average price is $13.40. The company has a market capitalization of $2.58 billion, a P/E ratio of -56.81 and a beta of 1.00.

Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.02). On average, research analysts expect that Trevi Therapeutics will post -0.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. KBC Group NV acquired a new position in Trevi Therapeutics during the first quarter worth about $29,000. Hilton Head Capital Partners LLC acquired a new stake in Trevi Therapeutics in the 4th quarter valued at about $40,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Trevi Therapeutics during the 4th quarter valued at about $50,000. Russell Investments Group Ltd. boosted its position in shares of Trevi Therapeutics by 194.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock valued at $25,000 after purchasing an additional 2,996 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Trevi Therapeutics by 32.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,231 shares of the company’s stock valued at $78,000 after purchasing an additional 1,523 shares in the last quarter. Institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

(Get Free Report)

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.

See Also